Showing Results for
- Academic Journals (888)
Search Results
- 888
Academic Journals
- 888
-
From:Review of Optometry (Vol. 140, Issue 5) Peer-ReviewedWe don't always get to stay in our comfort zone if we aim to practice comprehensive primary eye care. Sometimes, before we can write a prescription for therapy, we have to deal with uncomfortable situations. Discussing...
-
From:Ophthalmology Times (Vol. 28, Issue 11) Peer-ReviewedReviewed by James P. McCulley, MD Dallas -- Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month...
-
From:Family Practice News (Vol. 33, Issue 11)Vigamox Ophthalmic Solution (moxifloxacin ophthalmic solution 0.5%, Alcon Inc.) The Food and Drug Administration approved Vigamox ophthalmic solution 0.5% for treatment of bacterial conjunctivitis in children as...
-
From:Review of Optometry (Vol. 140, Issue 4) Peer-ReviewedThe first so-called "fourth-generation" topical fluoroquinolone has been approved. Zymar (gatifloxacin, Allergan) is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria....
-
From:Formulary (Vol. 38, Issue 6) Peer-ReviewedZymar Gatifloxacin ophthalmic solution, 0.3% ALLERGAN Fluoroquinolone approved for bacterial conjunctivitis Recent FDA approval of this fluoroquinolone ophthalmic solution makes it another option for the...
-
From:British Journal of Ophthalmology (Vol. 87, Issue 8) Peer-ReviewedAim: To compare the efficacy and safety of levofloxacin 0.5% ophthalmic solution (Quixin) with placebo for treatment of bacterial conjunctivitis. Methods: In this prospective, randomised, placebo controlled, double...
-
From:Ophthalmology Times (Vol. 28, Issue 3) Peer-ReviewedAlcon Inc. is asking the FDA to approve the ophthalmic use of moxifloxacin 0.5% ophthalmic solution for the treatment of bacterial conjunctivitis and ophthalmia neonatorum. Ophthalmia neonatorum is a bacterial...
-
From:Ophthalmology Times (Vol. 28, Issue 15) Peer-ReviewedReviewed by Harold R. Katz, MD Fort Lauderdale, FL--A 4-day course of moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon) is a safe and effective treatment for bacterial conjunctivitis in adults and children as...
-
From:Review of Optometry (Vol. 146, Issue 3) Peer-ReviewedConjunctivitis is one of the most common reasons for acute eye-related primary care visits. At a leading cornea service (Wills Eye Hospital), blepharo-conjunctivitis was the most common diagnosis in children, accounting...
-
From:Ophthalmology Times (Vol. 28, Issue 8) Peer-ReviewedReviewed by Mark Abelson, MD Andover, MA -- The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day...
-
From:Review of Optometry (Vol. 140, Issue 5) Peer-ReviewedThe FDA has approved the second "fourth-generation" topical fluoroquinolone, Vigamox (moxifloxacin, Alcon). It's indicated to treat bacterial conjunctivitis on a seven-day tid dosing regimen, and is approved for adults...
-
From:Ophthalmology Times (Vol. 28, Issue 9) Peer-ReviewedAlameda, CA -- The U.S. Patent & Trademark Office said InSite Vision Inc.'s patent gives the company sole rights to the use of azalide antibiotic formulations as a topical treatment of ocular infections. InSite...
-
From:Family Practice News (Vol. 34, Issue 3)ANAHEIM, CALIF. -- Povidone-iodine appears to be an effective treatment for bacterial and chlamydial conjunctivitis in children, Dr. Sherwin J. Isenberg reported at the annual meeting of the American Academy of...
-
From:Ophthalmology Times (Vol. 27, Issue 21) Peer-ReviewedAlameda, CA -- InSite Vision Inc.'s antibiotic product ISV-401 has proved safe and effective for treating acute bacterial conjunctivitis in a phase II clinical study. According to the company, the study shows that...
-
From:Family Practice News (Vol. 33, Issue 15)Vigamox (moxifloxacin HC1 ophthalmic solution) 0.5% is indicated for the treatment of bacterial conjunctivitis in adults and children who are aged 1 year and older. For more information on this product, contact Alcon...
-
From:MPR Pharmacists' Edition (Vol. 8, Issue 1)ALPHAGAN P Allergan Rx alpha-2 agonist. Brimonidine tartrate 0.1%, 0.15%; oph. soln; contains purite. Indications: Open-angle glaucoma. Ocular hypertension. Adults and Children: <2yrs: not recommended. [greater...
-
From:MPR Pediatricians' Edition (Vol. 25, Issue 2)* ACULAR Allerg Rx NSAID. Ketorolac tromethamine 0.5%; oph soln; contains benzalkonium chloride. Indications: Ocular itch due to seasonal allergic conjunctivitis. Post-op inflammation after cataract extraction....
-
From:Ophthalmology Times (Vol. 37, Issue 4) Peer-ReviewedTherapy for ocular allergy has shown significant progress in recent years. Topical antihistamine/mast cell stabilizers currently available provide a rapid relief of the primary symptoms of allergy, and the newest of...
-
From:Expert Review of Anti-infective Therapy (Vol. 10, Issue 1) Peer-ReviewedAuthor(s): Sheila West 1 Keywords : azithromycin; Chlamydia trachomatis ; mass treatment; neglected tropical disease; tetracycline; trachoma The leading infectious cause of blindness worldwide, trachoma, is...
-
From:MPR Pharmacists' Edition (Vol. 5, Issue 3)AZASITE Inspire Rx Macrolide. Azithromycin 1%; oph. soln; contains benzalkonium chloride. Indications: Susceptible bacterial conjunctivitis. Adults and Children: <1yr: not recommended. [greater than or equal...